<?xml version='1.0' encoding='utf-8'?>
<document id="22174437"><sentence text="Influence of SLCO1B1 polymorphisms on the drug-drug interaction between darunavir/ritonavir and pravastatin."><entity charOffset="13-20" id="DDI-PubMed.22174437.s1.e0" text="SLCO1B1" /><entity charOffset="72-81" id="DDI-PubMed.22174437.s1.e1" text="darunavir" /><entity charOffset="82-91" id="DDI-PubMed.22174437.s1.e2" text="ritonavir" /><entity charOffset="96-107" id="DDI-PubMed.22174437.s1.e3" text="pravastatin" /><pair ddi="false" e1="DDI-PubMed.22174437.s1.e0" e2="DDI-PubMed.22174437.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22174437.s1.e0" e2="DDI-PubMed.22174437.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22174437.s1.e0" e2="DDI-PubMed.22174437.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22174437.s1.e0" e2="DDI-PubMed.22174437.s1.e3" /><pair ddi="false" e1="DDI-PubMed.22174437.s1.e1" e2="DDI-PubMed.22174437.s1.e1" /><pair ddi="false" e1="DDI-PubMed.22174437.s1.e1" e2="DDI-PubMed.22174437.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22174437.s1.e1" e2="DDI-PubMed.22174437.s1.e3" /><pair ddi="false" e1="DDI-PubMed.22174437.s1.e2" e2="DDI-PubMed.22174437.s1.e2" /><pair ddi="false" e1="DDI-PubMed.22174437.s1.e2" e2="DDI-PubMed.22174437.s1.e3" /></sentence><sentence text="The authors investigated whether SLCO1B1 polymorphisms contribute to variability in pravastatin pharmacokinetics when pravastatin is administered alone versus with darunavir/ritonavir"><entity charOffset="84-95" id="DDI-PubMed.22174437.s2.e0" text="pravastatin" /><entity charOffset="118-129" id="DDI-PubMed.22174437.s2.e1" text="pravastatin" /><entity charOffset="164-173" id="DDI-PubMed.22174437.s2.e2" text="darunavir" /><entity charOffset="174-183" id="DDI-PubMed.22174437.s2.e3" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.22174437.s2.e0" e2="DDI-PubMed.22174437.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22174437.s2.e0" e2="DDI-PubMed.22174437.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22174437.s2.e0" e2="DDI-PubMed.22174437.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22174437.s2.e0" e2="DDI-PubMed.22174437.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22174437.s2.e1" e2="DDI-PubMed.22174437.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22174437.s2.e1" e2="DDI-PubMed.22174437.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22174437.s2.e1" e2="DDI-PubMed.22174437.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22174437.s2.e2" e2="DDI-PubMed.22174437.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22174437.s2.e2" e2="DDI-PubMed.22174437.s2.e3" /></sentence><sentence text=" HIV-negative healthy participants were prospectively enrolled on the basis of SLCO1B1 diplotype: group 1 (*1A/*1A, n = 9); group 2 (*1A/*1B, n = 10; or *1B/*1B, n = 2); and group 3 (*1A/*15, n = 1; *1B/*15, n = 5; or *1B/*17, n = 1)" /><sentence text=" Participants received pravastatin (40 mg) daily on days 1 through 4, washout on days 5 through 11, darunavir/ritonavir (600/100 mg) twice daily on days 12 through 18, with pravastatin 40 mg added back on days 15 through 18"><entity charOffset="23-34" id="DDI-PubMed.22174437.s4.e0" text="pravastatin" /><entity charOffset="100-109" id="DDI-PubMed.22174437.s4.e1" text="darunavir" /><entity charOffset="110-119" id="DDI-PubMed.22174437.s4.e2" text="ritonavir" /><entity charOffset="173-184" id="DDI-PubMed.22174437.s4.e3" text="pravastatin" /><pair ddi="false" e1="DDI-PubMed.22174437.s4.e0" e2="DDI-PubMed.22174437.s4.e0" /><pair ddi="false" e1="DDI-PubMed.22174437.s4.e0" e2="DDI-PubMed.22174437.s4.e1" /><pair ddi="false" e1="DDI-PubMed.22174437.s4.e0" e2="DDI-PubMed.22174437.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22174437.s4.e0" e2="DDI-PubMed.22174437.s4.e3" /><pair ddi="false" e1="DDI-PubMed.22174437.s4.e1" e2="DDI-PubMed.22174437.s4.e1" /><pair ddi="false" e1="DDI-PubMed.22174437.s4.e1" e2="DDI-PubMed.22174437.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22174437.s4.e1" e2="DDI-PubMed.22174437.s4.e3" /><pair ddi="false" e1="DDI-PubMed.22174437.s4.e2" e2="DDI-PubMed.22174437.s4.e2" /><pair ddi="false" e1="DDI-PubMed.22174437.s4.e2" e2="DDI-PubMed.22174437.s4.e3" /></sentence><sentence text=" Pharmacokinetic studies were conducted on day 4 (pravastatin alone) and day 18 (pravastatin + darunavir/ritonavir)"><entity charOffset="50-61" id="DDI-PubMed.22174437.s5.e0" text="pravastatin" /><entity charOffset="105-114" id="DDI-PubMed.22174437.s5.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.22174437.s5.e0" e2="DDI-PubMed.22174437.s5.e0" /><pair ddi="false" e1="DDI-PubMed.22174437.s5.e0" e2="DDI-PubMed.22174437.s5.e1" /></sentence><sentence text=" Pravastatin area under the plasma concentration-time curve (AUC(tau)) was 21% higher during administration with darunavir/ritonavir compared with pravastatin alone; however, this difference was not statistically significant (P = "><entity charOffset="1-12" id="DDI-PubMed.22174437.s6.e0" text="Pravastatin" /><entity charOffset="113-122" id="DDI-PubMed.22174437.s6.e1" text="darunavir" /><entity charOffset="123-132" id="DDI-PubMed.22174437.s6.e2" text="ritonavir" /><entity charOffset="147-158" id="DDI-PubMed.22174437.s6.e3" text="pravastatin" /><pair ddi="false" e1="DDI-PubMed.22174437.s6.e0" e2="DDI-PubMed.22174437.s6.e0" /><pair ddi="false" e1="DDI-PubMed.22174437.s6.e0" e2="DDI-PubMed.22174437.s6.e1" /><pair ddi="false" e1="DDI-PubMed.22174437.s6.e0" e2="DDI-PubMed.22174437.s6.e2" /><pair ddi="false" e1="DDI-PubMed.22174437.s6.e0" e2="DDI-PubMed.22174437.s6.e3" /><pair ddi="false" e1="DDI-PubMed.22174437.s6.e1" e2="DDI-PubMed.22174437.s6.e1" /><pair ddi="false" e1="DDI-PubMed.22174437.s6.e1" e2="DDI-PubMed.22174437.s6.e2" /><pair ddi="false" e1="DDI-PubMed.22174437.s6.e1" e2="DDI-PubMed.22174437.s6.e3" /><pair ddi="false" e1="DDI-PubMed.22174437.s6.e2" e2="DDI-PubMed.22174437.s6.e2" /><pair ddi="false" e1="DDI-PubMed.22174437.s6.e2" e2="DDI-PubMed.22174437.s6.e3" /></sentence><sentence text="11)" /><sentence text=" Group 3 variants had 96% higher pravastatin AUC(tau) on day 4 and 113% higher pravastatin AUC(tau) on day 18 compared with group 1" /><sentence text=" The relative change in pravastatin pharmacokinetics was largest in group 3 but did not differ significantly between diplotype groups"><entity charOffset="24-35" id="DDI-PubMed.22174437.s9.e0" text="pravastatin" /></sentence><sentence text=" In sum, the influence of SLCO1B1*15 and *17 haplotypes on pravastatin pharmacokinetics was maintained in the presence of darunavir/ritonavir"><entity charOffset="26-36" id="DDI-PubMed.22174437.s10.e0" text="SLCO1B1*15" /><entity charOffset="59-70" id="DDI-PubMed.22174437.s10.e1" text="pravastatin" /><entity charOffset="122-131" id="DDI-PubMed.22174437.s10.e2" text="darunavir" /><entity charOffset="132-141" id="DDI-PubMed.22174437.s10.e3" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.22174437.s10.e0" e2="DDI-PubMed.22174437.s10.e0" /><pair ddi="false" e1="DDI-PubMed.22174437.s10.e0" e2="DDI-PubMed.22174437.s10.e1" /><pair ddi="false" e1="DDI-PubMed.22174437.s10.e0" e2="DDI-PubMed.22174437.s10.e2" /><pair ddi="false" e1="DDI-PubMed.22174437.s10.e0" e2="DDI-PubMed.22174437.s10.e3" /><pair ddi="false" e1="DDI-PubMed.22174437.s10.e1" e2="DDI-PubMed.22174437.s10.e1" /><pair ddi="false" e1="DDI-PubMed.22174437.s10.e1" e2="DDI-PubMed.22174437.s10.e2" /><pair ddi="false" e1="DDI-PubMed.22174437.s10.e1" e2="DDI-PubMed.22174437.s10.e3" /><pair ddi="false" e1="DDI-PubMed.22174437.s10.e2" e2="DDI-PubMed.22174437.s10.e2" /><pair ddi="false" e1="DDI-PubMed.22174437.s10.e2" e2="DDI-PubMed.22174437.s10.e3" /></sentence><sentence text=" Because OATP1B1 inhibition would be expected to be greater in carriers of normal or high-functioning SLCO1B1 haplotypes, these findings suggest that darunavir/ritonavir is not a potent inhibitor of OATP1B1-mediated pravastatin transport in vivo"><entity charOffset="150-159" id="DDI-PubMed.22174437.s11.e0" text="darunavir" /><entity charOffset="160-169" id="DDI-PubMed.22174437.s11.e1" text="ritonavir" /><entity charOffset="216-227" id="DDI-PubMed.22174437.s11.e2" text="pravastatin" /><pair ddi="false" e1="DDI-PubMed.22174437.s11.e0" e2="DDI-PubMed.22174437.s11.e0" /><pair ddi="false" e1="DDI-PubMed.22174437.s11.e0" e2="DDI-PubMed.22174437.s11.e1" /><pair ddi="false" e1="DDI-PubMed.22174437.s11.e0" e2="DDI-PubMed.22174437.s11.e2" /><pair ddi="false" e1="DDI-PubMed.22174437.s11.e1" e2="DDI-PubMed.22174437.s11.e1" /><pair ddi="false" e1="DDI-PubMed.22174437.s11.e1" e2="DDI-PubMed.22174437.s11.e2" /></sentence><sentence text="" /></document>